Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
57 - How do you approach companies to support your organization?
-
Offering a voluntary advertising preclearance review program on a fee-for-service basis, the PAAB is a not-for-profit association with 11 association voting members and three individual members. The members include three major pharmaceutical industry trade associations, Innovative Medicines Canada, NDMAC and CGPA. The trade associations encourage their member companies to participate in the voluntary PAAB submission review preclearance program. Also, Health Canada, which is responsible under law for enforcing pharmaceutical advertising regulations has delegated the day to day role of guiding responsible, legal advertising to the PAAB. Health Canada recommends that all companies adhere to the PAAB Code of Advertising Acceptance. As part of a monitoring function, the PAAB staff will contact advertisers who are not following the PAAB code and advise them to send their advertising to the PAAB. Health Canada is copied for any necessary enforcement under the Food & Drugs Act.